Paul Singer’s Elliott Management Corp. and Mediapro have discussed the possibility of the U.S.
Keep Reading →
May 22 - Hedge Funds, Insider Trading - Comments
In wanting to sell Sears’ assets to his investment vehicle ESL, chief executive Eddie Lampert is tacitly admitting his tenure has been a failure.
Keep Reading →
May 4 - Hedge Funds, Insider Trading - Comments
Hedge fund Folger Hill Asset Management is merging with Schonfeld Strategic Advisors and returning capital to certain investors in May, according to an investor letter sent Tuesday...
Keep Reading →
April 11 - Hedge Funds, Insider Trading - Comments
What happened: Shares of Spectrum Pharmaceuticals, Inc.
Keep Reading →
March 7 - Market Movers, News - Comments
On September 14, 2016, the FDA’s Oncologic Drugs Advisory Committee met to evaluate and discuss a drug called apaziquone.
Keep Reading →
September 28 - News, Stock Analysis - Comments
When things go well in biotech, it can be a great ride.
Keep Reading →
September 16 - News, Stock Analysis - Comments
Next month, an advisory panel will get together to discuss, and rule upon, Spectrum Pharmaceuticals, Inc.
Keep Reading →
August 23 - News, Stock Analysis - Comments
In two separate filings with the U.S.
Keep Reading →
September 3 - Hedge Funds, News - Comments
Steven Boyd's Armistice Capital has further increased its activist stake in Spectrum Pharmaceuticals, Inc.
Keep Reading →
June 4 - Hedge Funds, News - Comments
Millennium Management, Spectrum Pharmaceuticals: Israel Englander and his hedge fund company Millennium Management now hold over 3.2 million shares of Spectrum Pharmaceuticals...
Keep Reading →
October 21 - Hedge Funds, News - Comments
Today, let's look at Tudor Investment, founded in 1980 by Paul Tudor Jones, and featuring the flagship Tudor BVI fund.
Keep Reading →
September 12 - Hedge Funds, News - Comments
Now, according to many of your fellow readers, hedge funds are viewed as delayed, old investment tools of a forgotten age.
Keep Reading →
September 6 - News - Comments
Editor's Note: Annaly Capital Management, Inc. (NYSE:NLY), American Capital Agency Corp. (NASDAQ:AGNC), CYS Investments Inc (NYSE:CYS), ARMOUR Residential REIT, Inc.
Keep Reading →
September 5 - News - Comments
Now, according to many market players, hedge funds are viewed as bloated, outdated investment tools of a forgotten age.
Keep Reading →
September 3 - News - Comments
If you were to ask many traders, hedge funds are seen as useless, outdated investment vehicles of a period lost to current times.
Keep Reading →
August 30 - News - Comments
In the financial world, there are many indicators shareholders can use to analyze Mr. Market. A pair of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 30 - News - Comments
For the last several years, certain stocks have remained cheap as the overwhelming presence of short sellers have made it more difficult for shares to break out.
Keep Reading →
July 12 - News - Comments
For the last five years, Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) CEO Rajesh Shrotriya has always insisted that Spectrum Pharmaceuticals, Inc.
Keep Reading →
July 8 - News - Comments
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) got crushed with a downgrade from Credit Suisse that led to a 6.3% loss on Monday.
Keep Reading →
June 25 - News - Comments
How can you double your investment literally overnight? Buy stocks of the right biotech companies.
Keep Reading →
June 13 - News - Comments
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was in 12 hedge funds' portfolio at the end of the first quarter of 2013.
Keep Reading →
June 6 - News - Comments
Is Idenix Pharmaceuticals Inc (NASDAQ:IDIX) an excellent stock to buy now? Investors who are in the know are taking a bearish view.
Keep Reading →
June 3 - News - Comments
In today’s marketplace, there are tons of metrics shareholders can use to track stocks. A couple of the most innovative are hedge fund and insider trading sentiment.
Keep Reading →
June 3 - News - Comments
What's the source of your investment strategy? Many look to great investors like Warren Buffett for guidance on how to invest.
Keep Reading →
May 13 - News - Comments
As I noted seven weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 17 - News - Comments
As I noted six weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 10 - News - Comments
Although the Nasdaq Composite is the only major U.S. index that's nowhere near its all-time high, it still turned in an impressive gain of 8.2% for the quarter.
Keep Reading →
April 7 - News - Comments
With the SPDR S&P Biotech (ETF) (NYSEARCA:XBI) up 28% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
March 17 - News - Comments
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
March 14 - News - Comments
Shaw is known as a math wizard and a quantitative investing pioneer. His firm is reportedly extremely selective, hiring less than 1% of applicants -- and Amazon.com, Inc.
Keep Reading →
March 14 - Hedge Funds - Comments
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) is hurting today after dialing back guidance for the year. Apparently the increased production by Sagent Pharmaceuticals Inc.
Keep Reading →
March 13 - News - Comments
After six straight record highs for the Dow Jones Industrial Average 2 Minute (Dow Jones Indices:.DJI), the market finally looks like it's running out of steam.
Keep Reading →
March 13 - News - Comments
Yesterday, I published an article titled, “When Being Short Backfires!” So it's only appropriate to look at the other side of the trade.
Keep Reading →
March 13 - News - Comments
Just 10 days ago, I examined the bear thesis on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) as, amazingly, over half of its float was sold short.
Keep Reading →
March 13 - News - Comments
Up until last week, Navistar International Corp (NYSE:NAV) traded with a one-year loss of 42%.
Keep Reading →
March 12 - News - Comments
What's the fastest growing drug in Celgene Corporation (NASDAQ:CELG)'s portfolio? It isn't Revlimid, Vidaza, or Abraxane.
Keep Reading →
February 20 - News - Comments
Earnings season is now starting to wind down, with most companies already having reported their quarterly results.
Keep Reading →
February 19 - News - Comments
Below are a handful of companies with impressive revenue growth rates over the past three years.
Keep Reading →
February 6 - News - Comments